Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$37 Mln
P/E Ratio
--
P/B Ratio
8.08
Industry P/E
87.38
Debt to Equity
0
ROE
-11.93 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-31.86 Mln
EBITDA
$-34.10 Mln
Net Profit
$-35.26 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
RenovoRx Inc (RNXT)
| -23.26 | -1.00 | -26.67 | -20.35 | -16.65 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
RenovoRx Inc (RNXT)
| -43.40 | -2.55 | -51.45 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.70 | 10,562.04 | 12.43 | 12.69 | |
| 73.09 | 10,050.19 | 97.07 | 2.52 | |
| 296.97 | 11,609.25 | 277.57 | 3.65 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an... oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Address: 4546 El Camino Real, Los Altos, CA, United States, 94022 Read more
Founder, Chairman of Board & Chief Medical Officer
Dr. Ramtin Agah M.D.
Founder, Chairman of Board & Chief Medical Officer
Dr. Ramtin Agah M.D.
Headquarters
Los Altos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of RenovoRx Inc (RNXT) stood at $ 16 Mln as on 31-Mar-25
The share price of RenovoRx Inc (RNXT) is $0.99 (NASDAQ) as of 29-Apr-2025 13:30 EDT. RenovoRx Inc (RNXT) has given a return of -16.65% in the last 3 years.
RenovoRx Inc (RNXT) has a market capitalisation of $ 37 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of RenovoRx Inc (RNXT) is 8.08 times as on 28-Apr-2025, a 125% premium to its peers’ median range of 3.59 times.
Since, TTM earnings of RenovoRx Inc (RNXT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the RenovoRx Inc (RNXT) and enter the required number of quantities and click on buy to purchase the shares of RenovoRx Inc (RNXT).
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Address: 4546 El Camino Real, Los Altos, CA, United States, 94022
The CEO & director of Dr. Ramtin Agah M.D.. is RenovoRx Inc (RNXT), and CFO & Sr. VP is Dr. Ramtin Agah M.D..
There is no promoter pledging in RenovoRx Inc (RNXT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,078
|
|
|
1,054
|
|
|
964
|
| RenovoRx Inc (RNXT) | Ratios |
|---|---|
|
Return on equity(%)
|
-183.84
|
|
Operating margin(%)
|
-7055.81
|
|
Net Margin(%)
|
-12344.19
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of RenovoRx Inc (RNXT) was $0 Mln.
$0.02
(
